{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028167","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.133021+00:00","generated_at":"2026-06-22T07:33:31.593955+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sangamo Therapeutics Q3 net loss $53.2M; revenue down, Fabry gene therapy expands","bullets":["Q3 net loss $53.2M ($0.34/shr) vs $47.7M ($0.33/shr) prior year; revenue $26.5M down from $28.6M.","Cash $350.3M at Sep 30 (Dec 31: $464.7M); raised $75.1M net from ATM Jan-Oct 2022.","FY2022 guidance narrowed: GAAP op expenses $315-325M, non-GAAP $280-290M (excl ~$35M SBC).","Fabry gene therapy STAAR expansion: 5 patients dosed at 5e13 vg/kg, including first two females; Phase 3 prep ongoing.","Hemophilia A (Pfizer) Phase 3 AFFINE trial recruitment resumed; pivotal readout expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028167","json":"https://secwatch.observer/filing/0001628280-22-028167.json","markdown":"https://secwatch.observer/filing/0001628280-22-028167.md","text":"https://secwatch.observer/filing/0001628280-22-028167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828022028167/0001628280-22-028167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828022028167/sgmo-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:33:31.593955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db28da0b6087d5a98518cef8c643eb0af96f3137","claim":"SANGAMO THERAPEUTICS, INC reported third quarter ended September 30, 2022 results: revenue 26.5 million, net income 53.2 million (net loss), EPS 0.34 per share (net loss).","evidence_excerpt":"Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. Revenues Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828022028167/0001628280-22-028167-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"26.5 million"},{"label":"Net income","value":"53.2 million (net loss)"},{"label":"EPS","value":"0.34 per share (net loss)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}